442847-11-2

Basic information

• Product Name: Phenol, 2-(1,1-dimethylethyl)-5-nitro-
• CAS NO: 442847-11-2
• Molecular Formula: C10H13NO3
• Molecular Weight: 195.218
• Mol File: 442847-11-2.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Phenol, 2-(1,1-dimethylethyl)-5-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 2-(1,1-dimethylethyl)-5-nitro-(442847-11-2)
• EPA Substance Registry System: Phenol, 2-(1,1-dimethylethyl)-5-nitro-(442847-11-2)

Safety Data

• Hazardous Substances Data: 442847-11-2(Hazardous Substances Data)

Upstream product

• 103392-84-3 2-tert-Butyl-5-nitro-phenylamine 
• 6310-21-0 2-(1,1-dimethylethyl)-benzenamine 

Downstream Products

• 35292-23-0 1-tert-butyl-2-methoxy-4-nitrobenzene 
• 35291-89-5 4-tert-butyl-3-methoxyaniline 
• 873055-37-9 2-(2-tert-butyl-5-aminophenoxy)ethanol 
• 873055-36-8 3-(2-ethoxyethoxy)-4-tert-butylbenzenamine 
• 873055-35-7 2-tert-butyl-5-aminophenol 
• 864372-63-4 tert-butyl-[2-(2-tert-butyl-5-nitro-phenoxy)-ethoxy]-dimethyl-silane 
• 442846-88-0 1-[2-(2-tert-butyl-5-nitro-phenoxy)-ethyl]-piperidine 

Relevant articles and documents

FERROPTOSIS INHIBITORS–DIARYLAMINE PARA-ACETAMIDES

Provided are compounds that inhibit ferroptosis activity, or modulate or inhibit a disease associated with ferroptosis dysregulation, such as neuropathy, ischemia reperfusion injury, acute kidney failure and cancer, including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.